Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boehringer Ingelheim commences phase III trial of breast cancer drug

Boehringer Ingelheim commences phase III trial of breast cancer drug

20th September 2010

Boehringer Ingelheim has begun a phase III clinical trial of its leading investigational compound afatinib among sufferers of metastatic breast cancer.

The new LUX-Breast 1 trial is the first pivotal study to evaluate afatinib – which is also being investigated as a lung cancer treatment – as an oral therapy for breast cancer patients.

It is thought that afatinib, which is intended to be marketed under the brand name Tomtovok, can inhibit both the epidermal growth factor receptor HER1 and the human epidermal receptor HER2, thereby preventing the development and spread of tumours.

Professor Klaus Dugi, corporate senior vice-president of medicine at Boehringer Ingelheim, said the trial has been initiated based on positive data from proof-of-concept studies.

He added: "We are delighted to be able to initiate this important trial together with a range of leading investigators to assess the value of afatinib for women with advanced breast cancer."

Last week, the company was granted European regulatory clearance to expand the labelling of its HIV drug Viramune, making it accessible to patients with an undetectable viral load regardless of their CD4 count.ADNFCR-8000103-ID-800071530-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.